Friday, February 28, 2020 4:16:01 PM
Most reports show the fatalities are due to respiratory failure which would include direct viral pneumonia plus secondary bacterial infection.In addition reports note severe pulmonary inflammation and fibrosis complicating the infection and resulting in respiratory failure and requiring mechanical ventilation.
Brilacidin's antibiotic, anti inflammatory and now possible antiviral effects seem to be ideal to combat the pulmonary effects of coronavirus.
The mechanism of it viral action seems to be the same as its bacterial mechanism of action. Brilacidin attaches to the bacterial cell wall and the viral protein coat which results in their lysis and subsequent destruction.
Brilacidin's anti inflammatory effects would help combat the excessive inflammation and scarring which results in blockage of the air sacs [aveoli] and small airways[bronchi] and ends in respiratory failure.
For IPIX this is a no risk venture. At a minimum Brilacidin is going to receive intensive and expensive study. At best it will be shown to be an important therapeutic to combat the corona virus epidemic.
My guess is the optimal therapy will include an antiviral plus an agent or agents {which could be Brilacidin} which would have an anti inflammatory and antibiotic effect. Brilacidin could be given as an IV dose early in the disease to prevent respiratory failure. As I recall its biologic effect is a number of days. Then it could be repeated later if needed.
Leo should be applauded for putting together this professional review. I have been trying to research these items all week and have only had partial success.
Another guess is the labs will complete their in vitro Brilacidin studies quickly. If they confirm Polymedix's early preclincal studies showing Brilacidin is effective against Coronavirus we will see a greatly accelerated FDA phase 3 study which will be done on a worldwide emergent basis at no cost to IPIX.
All the above is in my opinion only. It is an exciting time for IPIX and Brilacidin. We should know in a few weeks how things work out.
GLTA Farrell
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
Kona Gold Beverage, Inc. Updates Multi-Million Dollar Merger and Posts Over $1.2 Million in Q3 Revenues • KGKG • Nov 15, 2024 10:36 AM
HealthLynked Corp. Announces Third Quarter and Year-to-Date 2024 Results with Strategic Restructuring, Third-Party Debt Repayment, and Core Technology Focus • HLYK • Nov 15, 2024 8:00 AM
Alliance Creative Group (ACGX) Releases Q3 2024 Financial and Disclosure Report with an increase of over 100% in Net Income for 1st 9 months of 2024 vs 2023 • ACGX • Nov 14, 2024 8:30 AM
Unitronix Corp. Publishes Its Cryptocurrency Portfolio Strategy • UTRX • Nov 14, 2024 8:05 AM
Avant Technologies and Ainnova Tech Form Joint Venture to Advance Early Disease Detection Using Artificial Intelligence • AVAI • Nov 12, 2024 9:00 AM
Swifty Global Announces Launch of Swifty Sports IE, Expanding Sports Betting and Casino Services in the Irish Market • DRCR • Nov 12, 2024 9:00 AM